Baclofen is often considered a first-line treatment option for spasticity management in children
It can improve mobility in individuals with multiple sclerosis and also improve bowel and bladder function
Baclofen is a GABA B receptor agonist and is probably the most commonly prescribed antispasmodic in all patient populations dealing with spasticity, especially those with SCI [19,31]
Intrathecal baclofen pumps are small hockey-puck sized devices that release tiny amounts of baclofen into the space around the spinal column
Oral antispasmodic medications such as baclofen, tizanidine, and dantrium are used for initial management of spasticity and clonus while intrathecal baclofen may be used for severe symptom management [29, 30]
With the exception of diazepam, drugs used for muscle spasm, such as metaxalone and tizanidine, are not effective for treating spasticity
It is important for clinicians to have clear objectives in patient treatment and the available treatment strategies
Rebound symptoms of the ailments the medication is meant to treat, such as muscle rigidity and spasticity, can occur during baclofen withdrawal
Thus, the discontinuation of baclofen requires a slow taper
The baclofen works by inhibiting the GABA receptors in the nervous system
It relieves the spasms, cramping, and tightness of muscles caused by medical problems, including multiple sclerosis or certain injuries to the spine
Baclofen, a GABA-B agonist, is one of the most widely used drugs in treating abnormal or disabling spastic tone
1055/s-0034-1396012
About 10%-20% of people with multiple sclerosis (MS) receive baclofen to control their spasticity, but up to half of patients stop the medication in the first six months, a large Swedish